Liprostin™ is a treatment for PAD that has completed FDA Phase I and three Phase II clinical trials. We are in discussions with contract research organizations (“CRO”) for completion of our U.S. Food and Drug Administration (“FDA”) protocol for Phase III and submission of our new drug application for marketing in the US and its territories.
Transdermal PGE-1 Patch
The Transdermal PGE-1 Patch for the delivery of PGE-1 and / or Liprostin™ through the skin for the treatment of cardiovascular diseases is part of a group of 2 Provisional US Patents and 2 Non-Provisional US Patents filed in September 2016 by AngioSoma, Inc.
OmniCath I & OmniCath II
The OmniCath I is an atherectomy catheter that helps plaque removal by drilling, pulverizing and shaving it. The OmniCath I is protected by US Patent 5,728,129, and AngioSoma, Inc. is filing new patents currently which will, in conjunction with the original base patent, create the OmniCath™ II.
Soma Nutriceuticals, Inc.
Soma Nutriceuticals, Inc. provides patented nutraceutical products that increase muscle mass as well as non-patented nutraceutical products with proprietary formulas for aiding sleep, erections, stamina, and other uses.
David P. Summers, PhD
Robert L. Sonfield, Jr. esq
A. Tomas Garcia. III, MD
Jackie R. See MD, FACC
Our Press Releases
HOUSTON, TX (Marketwiredon September 21, 2017) – AngioSoma, Inc. (OTC: SOAN) — Esther & Esther management has high optimism that its revenue plan could prove successful. The publicly stated plan simply and efficiently drives high volume traffic and interested buyers directly to EstherandEsther.com. As noted in the previous press release (which can be read here), Read more about AngioSoma, Inc. (OTC: SOAN) Reports Esther & Esther Confident in New Revenue Plan[…]
AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform
Houston, TX, September 18, 2017 (PR.com) – AngioSoma, Inc. (OTC: SOAN) announces Agreement with Esther & Esther, Inc. to maximize sales of its OTC products with existing online marketing platform. Conjunctionally, the company’s subsidiary, Soma Nutraceuticals Inc., completed a licensing agreement with Kentucky-based East Kentucky Organic, Inc. to begin manufacturing of Soma Nutraceutical’s product line, Read more about AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform[…]
Houston, TX — (ReleaseWire) — 04/26/2017 — AngioSoma, Inc., (OTCMKTS:SOAN) recently filed its 10K for the period ending September 30, 2016 and its 10Q for the period ending December 31, 2016. AngioSoma, Inc.’s management would like to update its shareholders on recent progress within its 2017 business plan, including starting operations at its SOMA Nutraceuticals, Inc. Read more about AngioSoma, Inc. Starts SOMA Nutraceuticals, Inc.’s Operations[…]
With so many changes at AngioSoma, Inc. over the last month, we wanted to update our September 2016 shareholder presentation to correctly reflect what AngioSoma, Inc. has been doing. We have made the November 2016 AngioSoma, Inc. Shareholder Presentation available in both the PDF version and embedded here in its Microsoft PowerPoint version: © 2016 by Read more about November 2016 Shareholder Presentation[…]
MONTGOMERY, Texas — (BUSINESS WIRE, November 17, 2016 09:45 AM Eastern Standard Time) — AngioSoma, Inc. (OTCQB: SOAN) announces that its new subsidiary Soma Nutraceuticals, Inc. is the recipient of intellectual property conveyed by its Chairman Emeritus Dr. David Summers, including a nutraceutical product using either natural or synthetic nicotine in a patented method for Read more about AngioSoma, Inc. Acquires Patented Nutraceutical for Muscle Mass Development[…]
MONTGOMERY, TEXAS (Business Wire, November 4, 2016 at 9:36 AM CST) – AngioSoma, Inc. today announces that it was filing new improvements to its US Patent No. 5,728,129 and five predecessor patents 4,850,957; 4,994,067; 5,087,265; and 5,695,519; all of which will be used as “prior art” to the its newest catheter, the OmniCath® II. With Read more about AngioSoma, Inc. to upgrade its OmniCath Patents into OmniCath 2 Atherectomy Catheter[…]
Released on October 25, 2016, Uptick Newswire’s Jasyn Blair interviewed Dr. Dr. David Summers, AngioSoma, Inc.’s Chairman Emeritus (entitled “Dr. David Summers, AngioSoma Inc., Talks Entering Joint Venture to Commercialize their Signature Product“. We also make it available here: Other media outlets covering the interview… Investors Hangout (Front Page) iTunes iHeartRADIO Google Play Audio Boom! Read more about Uptick Newswire talks with Dr. David Summers[…]
MONTGOMERY, TEXAS (Business Wire, October 20, 2016) – AngioSoma, Inc. (OTCQB SOAN) is in final negotiations with Dr. Jackie R. See, M.D., F.A.C.C. to join its Scientific Advisory Board. Dr. See was instrumental in the original development of liposomal PGE-1 and is involved in new, and still experimental, uses of PGE-1 and stem cell treatment Read more about Dr. Jackie R. See MD joins AngioSoma, Inc.’s Scientific Advisory Board[…]
MONTGOMERY, Texas — (BUSINESS WIRE,October 11, 2016 09:00 AM Eastern Daylight Time) — AngioSoma, Inc. (OTCQB: SOAN) filed three (3) new patent applications associated with Liprostin™, adding to the Company’s product pipeline and supplementing the intellectual property already conveyed by Chairman Emeritus Dr. David P. “Doc” Summers, PhD, FACA. The new patents include transdermal skin Read more about AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™[…]
MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN) announces a joint venture with La Jolla Capital Partners LLC (‘La Jolla’) focused on the funding and management of US Food and Drug Administration (‘FDA’) Liprostin™ Phase III trials, as well as the licensing of Liprostin™ worldwide thereafter. Liprostin™ is a liposomal encapsulated prostaglandin e1 (‘PGE1’) and is AngioSoma, Inc.’s Read more about AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture[…]